Preston R McMullin1, Alexander Thomas Hynes2, Mohammed Ahnaf Arefin2, Moawiz Saeed1, Sarvani Gandhavadi2, Nuha Arefin3, Maxim S Eckmann4. 1. Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, USA. 2. Department of Anesthesiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, USA. 3. University of Texas at Dallas, 800 W Campbell Road, Richardson, TX, USA. 4. Department of Anesthesiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, USA. eckmann@uthscsa.edu.
Abstract
PURPOSE OF REVIEW: Neuropathic pain is a prevalent and burdensome condition. While oral medical therapies are the first-line treatment for refractory neuropathic pain, in some cases, infusion therapy may be employed. This article is a systematic review of recent publications regarding epidemiologic, pathophysiologic, diagnostic, and therapeutic advancements in the treatment of neuropathic pain using intravenous infusion therapy. Special consideration will be given to relevant and practically used agents and available information on outcomes. RECENT FINDINGS: Individuals with neuropathic pain from various etiologies (e.g. trigeminal neuralgia, post-herpetic neuralgia, diabetic neuropathy) often find short-term relief from infusion therapies. However, it is difficult to generalize the findings of these studies to form a standard treatment regimen. The purpose of this paper is to provide clinicians an up-to-date summary of recent literature regarding several infusion therapies in treating neuropathic pain.
PURPOSE OF REVIEW: Neuropathic pain is a prevalent and burdensome condition. While oral medical therapies are the first-line treatment for refractory neuropathic pain, in some cases, infusion therapy may be employed. This article is a systematic review of recent publications regarding epidemiologic, pathophysiologic, diagnostic, and therapeutic advancements in the treatment of neuropathic pain using intravenous infusion therapy. Special consideration will be given to relevant and practically used agents and available information on outcomes. RECENT FINDINGS: Individuals with neuropathic pain from various etiologies (e.g. trigeminal neuralgia, post-herpetic neuralgia, diabetic neuropathy) often find short-term relief from infusion therapies. However, it is difficult to generalize the findings of these studies to form a standard treatment regimen. The purpose of this paper is to provide clinicians an up-to-date summary of recent literature regarding several infusion therapies in treating neuropathic pain.
Authors: Ke Xu; John H Krystal; Yuping Ning; Da Chun Chen; Hongbo He; Daping Wang; Xiaoyin Ke; Xifan Zhang; Yi Ding; Yuping Liu; Ralitza Gueorguieva; Zuoheng Wang; Diana Limoncelli; Robert H Pietrzak; Ismene L Petrakis; Xiangyang Zhang; Ni Fan Journal: J Psychiatr Res Date: 2014-12-24 Impact factor: 4.791
Authors: Brian C Callaghan; Hsinlin T Cheng; Catherine L Stables; Andrea L Smith; Eva L Feldman Journal: Lancet Neurol Date: 2012-05-16 Impact factor: 44.182
Authors: Joachim Scholz; Nanna B Finnerup; Nadine Attal; Qasim Aziz; Ralf Baron; Michael I Bennett; Rafael Benoliel; Milton Cohen; Giorgio Cruccu; Karen D Davis; Stefan Evers; Michael First; Maria Adele Giamberardino; Per Hansson; Stein Kaasa; Beatrice Korwisi; Eva Kosek; Patricia Lavand'homme; Michael Nicholas; Turo Nurmikko; Serge Perrot; Srinivasa N Raja; Andrew S C Rice; Michael C Rowbotham; Stephan Schug; David M Simpson; Blair H Smith; Peter Svensson; Johan W S Vlaeyen; Shuu-Jiun Wang; Antonia Barke; Winfried Rief; Rolf-Detlef Treede Journal: Pain Date: 2019-01 Impact factor: 7.926